Liver Transplantation Because most patients with primary HCC in this country have underlying liver disease, liver transplantation allow the best chance for cure. NewYork-Presbyterian/Columbia University Medical Center boasts one of the largest and most experienced liver transplantation programs in the nation, offering living donor liver transplantation and employing minimally invasive surgical approaches whenever possible.
Liver transplant procedures at the CLDT take advantage of the most sophisticated medical knowledge and surgical technology available today, including living donor transplantation, partial liver transplantation, advanced organ preservation techniques, liver transplantation in HIV- and Hepatitis C co-infected individuals, and antiviral therapy to prevent or treat recurrent hepatitis C after liver transplantation.
The Living Donor Liver Transplant program is one of the largest living donor liver programs in North America. We have performed more than 220 living donor liver transplants since its inception. We have performed more left lobe donations than any other living donor liver program in North America and introduced fully laparoscopic donation for all pediatric liver donor liver transplants in 2009.
Our program routinely achieves excellent outcomes for donors and recipients. Our recipients have 97.1 percent one-year survival after transplantation and a three-year survival of 93.3 percent. Additionally, nearly all donors are very satisfied or satisfied with the experience of donating a portion of their liver. After surgery, we also offer specialized nursing, nutritional support, smoking cessation, weight loss and pain management.
Columbia's Jean C. Emond, MD, was a member of the team that pioneered living donor liver transplantation, now considered one of the most important advances in the treatment of severe liver disease. Approximately 15 to 20 percent of the center's transplant patients currently receive a liver from a living donor. Dr. Benjamin Samstein has led the program since 2008, introducing laparoscopy.
Columbia is also one of only a few centers in the country which offers liver transplantation for selected patients with bile duct cancers. For patients who are unresectable, this procedure can offer an unprecedented chance for cure.
Resection: For patients who do not have significant underlying liver damage, often our surgeons can remove the tumor surgically without a transplant. This is called resection. Dr. Tomoaki Kato has pioneered a technology called “ex vivo” resection which allows removal of tumors which have been considered traditionally unresectable, again offering a chance for cure